Tag - TRVI

Feature

Trevi reinventing chronic cough treatment with a dual-action approach to hypersensitivity

Trevi Therapeutics (NASDAQ: TRVI) is advancing a fundamentally different approach to the treatment of chronic cough—a high unmet need that significantly affects the quality of life for millions of Americans.

November 25, 2025

Developments

Trevi reports positive Phase 2a trial data of Haduvio for RCC

Trevi Therapeutics (NASDAQ:TRVI) announced positive topline results from its Phase 2a RIVER study of oral nalbuphine ER (Haduvio) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF)...

March 10, 2025

Markets

SVB starts Trevi Therapeutics at OP; PT $6

SVB Securities initiated coverage of Trevi Therapeutics (NASDAQ:TRVI) with an “outperform” rating and $6 price target. The stock closed at $1.99 on Nov. 21. TRVI is a clinical-stage biopharmaceutical company developing...

November 22, 2022

Tag - TRVI

Trevi reinventing chronic cough treatment with a dual-action approach to hypersensitivity

Trevi reports positive Phase 2a trial data of Haduvio for RCC

SVB starts Trevi Therapeutics at OP; PT $6

Subscribe